{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:14:10Z","timestamp":1756682050336},"reference-count":58,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T00:00:00Z","timestamp":1293580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Despite improvements in therapy that has greatly enhanced the treatment of patients with haemophilia with inhibitors, they are still at risk of poorer outcomes including haemophilic arthropathy and long\u2010term disability. The objective of this review is to consider clinical data on the effect of rapid control of bleeding episodes on outcomes in these patients. Rapid control of bleeding episodes using bypassing agents has the potential to minimize joint damage and to improve quality of life. Consideration of strategies to support rapid control of bleeding \u2013 including patient education and awareness, and timely administration of clotting factor \u2013 is important.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2010.02337.x","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T06:12:52Z","timestamp":1277100772000},"page":"11-16","source":"Crossref","is-referenced-by-count":10,"title":["Importance of rapid bleeding control in haemophilia complicated by inhibitors"],"prefix":"10.1111","volume":"17","author":[{"given":"E.","family":"BERNTORP","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01518.x"},{"key":"e_1_2_6_3_2","volume-title":"Inhibitors in Haemophilia: A Primer","author":"Di Michele DM","year":"2008"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01947.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1457"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01204.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00059.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01128.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01075.x"},{"issue":"1","key":"e_1_2_6_12_2","first-page":"S93","article-title":"Safety, efficacy and cost\u2010effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti\u2010factor VIII inhibitor","volume":"9","author":"Stewart AJ","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early treatment with recombinant factor VIIa results in greater efficacy with less product","volume":"63","author":"Lusher JM","year":"1998","journal-title":"Eur J Haematol Suppl"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NOR.0000315623.59385.2b"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01892.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06087.x"},{"key":"e_1_2_6_17_2","unstructured":"World Federation of Hemophilia.Guidelines for the Management of Hemophilia.2005. Accessible from the World Federation of Hemophilia athttp:\/\/www.wfh.org. Accessed June 2 2010."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01931.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01516.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06534.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01601.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01284.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02179.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01625.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204030-00002"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37942"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-922223"},{"key":"e_1_2_6_32_2","article-title":"The need for speed in the management of haemophilia patients with inhibitors","author":"Salek SZ","year":"2010","journal-title":"Haemophilia"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80844-X"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01956.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01772.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02007.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.3111\/200205119133"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822020-00005"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02012.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01268.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01882.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01973.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02077.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01736.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01887.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02126.x"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2005.075234"},{"key":"e_1_2_6_49_2","article-title":"Knowledge and behaviors regarding complication and prevention of patients with hemophila in Korea","volume":"5","author":"Choi K","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02017.x"},{"key":"e_1_2_6_51_2","first-page":"121","article-title":"Implementation of on\u2010demand treatment protocol in adult patients with severe haemophilia by an emerging program for comprehensive care of haemophilia: preliminary results. Poster 25 PO 15","volume":"14","author":"Zuniga P","year":"2008","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_6_52_2","first-page":"S107","article-title":"Home treatment with recombinant activated factor VII: results from one centre","volume":"9","author":"Ingerslev J","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01926.x"},{"key":"e_1_2_6_54_2","first-page":"222","article-title":"Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86\u20106150) for acute and prophylactic treatments in hemophilia A (HemA) mice","volume":"7","author":"Liu T","year":"2009","journal-title":"J Thromb Haemost"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-04-0268"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(08)70029-X"},{"key":"e_1_2_6_57_2","first-page":"826","article-title":"Functional characterization of a new recombinant FVIII (N8)","volume":"7","author":"Kjalke M","year":"2009","journal-title":"J Thromb Haemost"},{"key":"e_1_2_6_58_2","first-page":"15","article-title":"A phase II open\u2010label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI\u20101) in hemophilia A patients with inhibitors directed against human FVII","volume":"14","author":"Mahlangu J","year":"2008","journal-title":"Haemophilia"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01451.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02337.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2010.02337.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T18:10:59Z","timestamp":1711563059000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02337.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1365-2516.2010.02337.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02337.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,29]]}}}